IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment

EMBO Molecular Medicine

Volumn 8, Issue 9, 2016, Pages 1099-1112

  Davidson, Sophia ^a   McCabe, Teresa M ^a   Crotta, Stefania ^a   Gad, Hans Henrik ^b   Hessel, Edith M ^c   Beinke, Soren ^c   Hartmann, Rune ^b   Wack, Andreas ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

immunopathology; infection; influenza; interferon alpha; interferon lambda

Indexed keywords

ALPHA INTERFERON; CYTOKINE; PEGINTERFERON LAMBDA;

ADULT; AIRWAY EPITHELIAL CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENCY; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; INFLUENZA A; INNATE IMMUNITY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

EID: 84984804780     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201606413     Document Type: Article

References (59)

1. Agrati C, Gioia C, Lalle E, Cimini E, Castilletti C, Armignacco O, Lauria FN, Ferraro F, Antonini M, Ippolito G et al (2010) Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis 202: 681–689
2. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H et al (2008) An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474–2485
3. Arankalle VA, Lole KS, Arya RP, Tripathy AS, Ramdasi AY, Chadha MS, Sangle SA, Kadam DB (2010) Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS One 5: e13099
4. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, Garcia-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH et al (2009) Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA 106: 3455–3460
5. Blazek K, Eames HL, Weiss M, Byrne AJ, Perocheau D, Pease JE, Doyle S, McCann F, Williams RO, Udalova IA (2015) IFN-lambda resolves inflammation via suppression of neutrophil infiltration and IL-1beta production. J Exp Med 212: 845–853
6. Ciancanelli MJ, Huang SX, Luthra P, Garner H, Itan Y, Volpi S, Lafaille FG, Trouillet C, Schmolke M, Albrecht RA et al (2015) Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 348: 448–453
7. Cilloniz C, Pantin-Jackwood MJ, Ni C, Carter VS, Korth MJ, Swayne DE, Tumpey TM, Katze MG (2012) Molecular signatures associated with Mx1-mediated resistance to highly pathogenic influenza virus infection: mechanisms of survival. J Virol 86: 2437–2446
8. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, Staeheli P, Wack A (2013) Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog 9: e1003773
9. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G (2009) IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 113: 5829–5838
10. Davidson S, Crotta S, McCabe TM, Wack A (2014) Pathogenic potential of interferon alphabeta in acute influenza infection. Nat Commun 5: 3864
11. Davidson S, Maini MK, Wack A (2015) Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res 35: 252–264
12. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R (2009) Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 10: 125–131
13. Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I, Durand SC, Heydmann L, Zeisel MB, Baumert TF et al (2014) IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J Exp Med 211: 857–868
14. Durbin RK, Kotenko SV, Durbin JE (2013) Interferon induction and function at the mucosal surface. Immunol Rev 255: 25–39
15. Egli A, Santer DM, O'Shea D, Barakat K, Syedbasha M, Vollmer M, Baluch A, Bhat R, Groenendyk J, Joyce MA et al (2014a) IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog 10: e1004556
16. Egli A, Santer DM, O'Shea D, Tyrrell DL, Houghton M (2014b) The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect 3: e51
17. Ehrhardt C, Seyer R, Hrincius ER, Eierhoff T, Wolff T, Ludwig S (2010) Interplay between influenza A virus and the innate immune signaling. Microbes Infect 12: 81–87
18. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ et al (2012) IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484: 519–523
19. Finter NB, Chapman S, Dowd P, Johnston JM, Manna V, Sarantis N, Sheron N, Scott G, Phua S, Tatum PB (1991) The use of interferon-alpha in virus infections. Drugs 42: 749–765
20. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S et al (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446: 916–920
21. de Groen RA, Boltjes A, Hou J, Liu BS, McPhee F, Friborg J, Janssen HL, Boonstra A (2015a) IFN-lambda-mediated IL-12 production in macrophages induces IFN-gamma production in human NK cells. Eur J Immunol 45: 250–259
22. de Groen RA, Groothuismink ZM, Liu BS, Boonstra A (2015b) IFN-lambda is able to augment TLR-mediated activation and subsequent function of primary human B cells. J Leukoc Biol 98: 623–630
23. Hale BG, Randall RE, Ortin J, Jackson D (2008) The multifunctional NS1 protein of influenza A viruses. J Gen Virol 89: 2359–2376
24. Haller O, Staeheli P, Schwemmle M, Kochs G (2015) Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol 23: 154–163
25. Hayden FG, de Jong MD (2011) Emerging influenza antiviral resistance threats. J Infect Dis 203: 6–10
26. Hogner K, Wolff T, Pleschka S, Plog S, Gruber AD, Kalinke U, Walmrath HD, Bodner J, Gattenlohner S, Lewe-Schlosser P et al (2013) Macrophage-expressed IFN-beta contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog 9: e1003188
27. Horisberger MA, Staeheli P, Haller O (1983) Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc Natl Acad Sci USA 80: 1910–1914
28. Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D (2006) Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 3: CD001265
29. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC et al (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203–1207
30. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G (2007) Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 8: 13–20
31. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim JH, Halfmann P, Hatta M et al (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319–323
32. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, Kotenko SV, Sideras P, Lehr HA, Tepe M et al (2011) IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 3: 348–361
33. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69–77
34. Krammer F, Palese P, Steel J (2015) Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol 386: 301–321
35. Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, Kobasa D, Haller O, Staeheli P, von Messling V (2009) Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 83: 3843–3851
36. Lasfar A, Cook JR, Cohen Solal KA, Reuhl K, Kotenko SV, Langer JA, Laskin DL (2014) Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response. Immunology 142: 442–452
37. Lauber C, Vieyres G, Terczynska-Dyla E, Anggakusuma Dijkman R, Gad HH, Akhtar H, Geffers R, Vondran FW, Thiel V, Kaderali L et al (2015) Transcriptome analysis reveals a classical interferon signature induced by IFNlambda4 in human primary cells. Genes Immun 16: 414–421
38. Liu BS, Janssen HL, Boonstra A (2011) IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood 117: 2385–2395
39. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA et al (2009) Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 302: 1896–1902
40. McKinlay MA (2001) Recent advances in the treatment of rhinovirus infections. Curr Opin Pharmacol 1: 477–481
41. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P (2008) Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4: e1000151
42. Moro K, Kabata H, Tanabe M, Koga S, Takeno N, Mochizuki M, Fukunaga K, Asano K, Betsuyaku T, Koyasu S (2016) Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat Immunol 17: 76–86
43. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T et al (2014) A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol 61: 1238–1246
44. Pavlovic J, Haller O, Staeheli P (1992) Human and mouse Mx proteins inhibit different steps of the influenza virus multiplication cycle. J Virol 66: 2564–2569
45. Pavlovic J, Arzet HA, Hefti HP, Frese M, Rost D, Ernst B, Kolb E, Staeheli P, Haller O (1995) Enhanced virus resistance of transgenic mice expressing the human MxA protein. J Virol 69: 4506–4510
46. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL et al (2004) Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363: 617–619
47. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, Staeheli P, Hornef MW (2011) IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA 108: 7944–7949
48. Randall RE, Goodbourn S (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1–47
49. Salomon R, Staeheli P, Kochs G, Yen HL, Franks J, Rehg JE, Webster RG, Hoffmann E (2007) Mx1 gene protects mice against the highly lethal human H5N1 influenza virus. Cell Cycle 6: 2417–2421
50. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63–68
51. Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017
52. Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, Andoniou CE, Degli-Esposti MA, Hill GR, Smyth MJ (2015) NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci USA 112: E2376–E2384
53. Staeheli P, Dreiding P, Haller O, Lindenmann J (1985) Polyclonal and monoclonal antibodies to the interferon-inducible protein Mx of influenza virus-resistant mice. J Biol Chem 260: 1821–1825
54. Suzuki Y, Ito T, Suzuki T, Holland RE Jr, Chambers TM, Kiso M, Ishida H, Kawaoka Y (2000) Sialic acid species as a determinant of the host range of influenza A viruses. J Virol 74: 11825–11831
55. Tovey MG, Maury C (1999) Oromucosal interferon therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res 19: 145–155
56. Trinchieri G (2010) Type I interferon: friend or foe? J Exp Med 207: 2053–2063
57. Tumpey TM, Szretter KJ, Van Hoeven N, Katz JM, Kochs G, Haller O, Garcia-Sastre A, Staeheli P (2007) The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol 81: 10818–10821
58. Wack A, Terczynska-Dyla E, Hartmann R (2015) Guarding the frontiers: the biology of type III interferons. Nat Immunol 16: 802–809
59. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, Ren Y, Wang J, Dong Y, Bao M et al (2014) Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 111: 769–774